GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.
GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.
Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.
CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”
____
Most Popular
Alibaba Group (BABA) Q2 2025 Earnings: Key financials and quarterly highlights
Alibaba Group Holding Limited (NYSE: BABA) reported its second quarter 2025 earnings results today. Revenue was $33.7 billion, up 5% year-over-year. Net income attributable to ordinary shareholders grew 58% to
AMAT Earnings: Applied Materials Q4 revenue and profit increase YoY
Applied Materials, Inc. (NASDAQ: AMAT) announced financial results for the fourth quarter of 2024, reporting an increase in revenue and adjusted earnings. Adjusted earnings of the semiconductor technology company increased
What to expect when Target (TGT) reports its Q3 2024 earnings results
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday. The stock has gained 9% over the past three months. The retailer is scheduled to report its earnings results for
